Angle PLC - European patent granted for megakaryocyte analysis
For immediate release
4 October 2019
EUROPEAN PATENT GRANTED TO QUEEN MARY UNIVERSITY
ANGLE holds worldwide exclusive option over all megakaryocyte intellectual property
Presence of megakaryocytes in prostate cancer linked to patient survival
ANGLE has an option agreement, exercisable up until
QMUL published research in
Investigation of megakaryocytes in patient blood opens up the potential for a whole new area for cancer prognosis and, at present, ANGLE's patented Parsortix system is the only automated system that has demonstrated the capability of harvesting megakaryocytes. Alternative liquid biopsy approaches such as ctDNA (fragments of dead cells) cannot assess the presence of megakaryocytes.
ANGLE now has the potential for intellectual property protection over the upstream megakaryocyte cell capture technology (its existing Parsortix IP) and the downstream megakaryocyte analysis technology (via its option over the patent grant announced today). The protection of key intellectual property is an essential part of ANGLE's differentiated and highly leveraged product-based commercialisation strategy.
The Parsortix system has previously been shown to be capable of harvesting mesenchymal circulating tumor cells (CTCs), which are linked to a poor patient outcome. Circulating megakaryocytes are linked to a more favourable patient outcome. Combining these two factors may provide new insights into assessing the prognosis of prostate cancer patients, allowing stratified treatment.
ANGLE Founder and Chief Executive,
"We welcome the acceptance of this European patent and are excited by the potential for this entirely new way of assessing cancer through a simple blood test that has been enabled by ANGLE's Parsortix system. We will now be investigating the possibility of adding megakaryocyte tests to our existing CTC tests as part of our sample-to-answer imaging solution under development."
"We are pleased to see the grant of the European patent for the analysis of megakaryocytes in patient blood as a prognostic biomarker with the potential to open up new avenues in the fight against cancer. We look forward to working with ANGLE to bring this analysis to patients as soon as possible."
"We believe megakaryocytes in patient blood may play a key role in the body's immune response to all solid cancer types, not just prostate cancer. We are currently investigating this hypothesis in several other cancer types to maximise the potential of megakaryocyte analysis."
For further information ANGLE:
| || |
+44 (0) 1483 343434
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance -
+44 (0)20 7220 0500
+44 (0) 203 705 9330
+44 (0) 203 727 1000
+1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix® system, and it enables a liquid biopsy (a simple blood test) to be used to provide the cells of interest to the user in a format suitable for multiple downstream subsequent analyses. CTCs enable the complete picture of a cancer to be seen as they allow DNA, RNA and protein analysis and the live cells harvested can be cultured. The Parsortix technology is the subject of 24 granted patents in
ANGLE's technology for the multiplex evaluation of proteins and nucleic acids of all types is called the HyCEADTM Ziplex® platform and is based on a patented flow through array technology. It provides for low cost, highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types. A proprietary chemistry approach (the HyCEAD method) allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction. The HyCEAD Ziplex system is ideal for measuring gene expression and other markers directly from Parsortix harvests and was used in the ovarian cancer pelvic mass triage test to achieve best in class accuracy (ROC-AUC) of 95.1%.
ANGLE's proprietary technologies can be combined to provide automated, sample-to-answer results in both centralised laboratory and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class cancer centres and major corporates such as Abbott, Philips and QIAGEN, and works closely with leading CTC translational research customers. These Key Opinion Leaders (KOLs) are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. The body of evidence as to the benefits of the Parsortix system is growing rapidly from our own clinical studies in metastatic breast cancer and ovarian cancer and also from KOLs with 25 peer-reviewed publications and numerous publicly available posters, available on our website.
This information is provided by RNS, the news service of the
Quick facts: ANGLE PLC
Market Cap: £105.41 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE